Dynavax Technologies (DVAX)

• Market cap: $1.31B
• 1 day: 3.52%
• 5 days: 1.45%
• 1 month: 10.47%
• 3 months: 2.1%
• 6 months: 12.93%
• Year to date: -13.33%
• 1 year: -9.55%
• 5 years: 166.19%
• 10 years: -55.53%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Employees: 405